| |
NewswireTODAY - /newswire/ -
Monrovia, CA, United States, 2013/11/25 - Allen D. Roses, President of Barbaresco Pharmaceuticals To Give a Plenary Keynote Presentation on “A post-GWAS Method for Translating Statistical Associations to Disease-relevant Pathways” at the Biomarker Summit 2014 (March 19-21, 2014 in San Diego.
|
| |
In Dr. Allen Roses’ presentation, he will discuss how a highly polymorphic structural polyT marker at a single locus [rs10524523] in intron 6 of TOMM40 was found to extend the association of APOE4 to include APOE3 and APOE2. The TOMM40 data are informative in the Caucasian population for prediction of the onset of Mild Cognitive Impairment due to Alzheimer’s disease over the next five years, for 97% of Caucasians, based on age and genotype between 65-83 years old. This led to the translation of these data to a Phase III trial [TOMMorrow trial, Zinfandel-Takeda Alliance] for the delay of onset of MCI-AD using low-dose piogtitazone.
Dr. Allen D. Roses will also discuss how widespread GWAS analyses have produced extensive gene lists [termed candidate genes] for association to a particular disease but to date there has been little translation or further selection of loci for in depth analyses. By creating lists of candidate genes that reflect the biological history of the proposed mechanisms for a complex disease, and which may now add the products of GWAS studies, it is possible to rapidly screen genes for co-localization of structural polymorphisms. Structural mutations are usually located within introns or in other non-coding regions, and may not be recognized by genomic next-generation sequencing or exome methods. This platform leads to specific locations for phylogenetic analyses and identification of pathological polymorphisms associated with complex diseases.
Dr. Allen D. Roses serves in several capacities at Duke University: as Jefferson-Pilot Professor of Neurobiology and Genetics, as Director of the Deane Drug Discovery Institute, and as Senior Scholar at the Fuqua School of Business. He recently returned to Duke University after a decade-long career as a Senior Vice President at GlaxoSmithKline (GSK) where he headed research in clinical genetics, genomics, proteomics, pharmacogenetics, and bioinformatics in support of the entire R&D pipeline. He was one of the first clinical neurologists to apply molecular genetics strategies to neurological diseases and he led the team that in 1992 identified APOE as a major, widely confirmed susceptibility gene in common late-onset Alzheimer's disease.
The Biomarker Summit 2014 brings together experts from industry, academia and non-profit organizations to discuss the latest developments in the biomarker and diagnostics field. The summit will consist of three parallel tracks focused on different therapeutic areas:
1) 7th Oncology Biomarkers
2) 3rd Neurological Biomarkers
3) 3rd Inflammatory & Immunological Biomarkers.
|
infogtcbio[.]gtcbio.com 
